Learn more about whether Protagonist Therapeutics, Inc. or Roivant Sciences Ltd. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

KBC Group NV increased its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 54.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the ...

Learn more about whether Protagonist Therapeutics, Inc. or Twist Bioscience Corporation is a better investment based on ...

JMP Securities reiterated their market outperform rating on shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) in a research report report published on Friday,Benzinga reports. They ...

Protagonist Pictures will launch Stan Original rom-com 'One More Shot' for international sales at this year's European Film ...

Truist Securities reiterated its Buy rating and $60.00 price target for Protagonist Therapeutics (NASDAQ:PTGX) shares, which currently trade at $38.78 with a market capitalization of $2.3 billion. The ...

In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on Protagonist Therapeutics (PTGX – Research Report), with a ...

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Protagonist Therapeutics (PTGX – Research ...

Protagonist Pictures is launching world sales at the EFM on Australian filmmaker Nicholas Clifford time travelling romantic ...

Protagonist Pictures is launching world sales at the EFM on time travel romantic comedy One More Shot, starring American Gods’ Emily Browning, ahead of its world premiere at SXSW. Australian filmmaker ...

JMP Securities reiterated its Market Outperform rating on Protagonist Therapeutics (NASDAQ:PTGX) with a steady price target ...